Tharimmune (THAR) Competitors $3.52 +0.17 (+5.07%) As of 05/22/2026 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock THAR vs. AURA, AVTX, PRTA, ALLO, and ANLShould you buy Tharimmune stock or one of its competitors? MarketBeat compares Tharimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tharimmune include Aura Biosciences (AURA), Avalo Therapeutics (AVTX), Prothena (PRTA), Allogene Therapeutics (ALLO), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. THAR vs. AURATHAR vs. AVTXTHAR vs. PRTATHAR vs. ALLOTHAR vs. ANLHow does Tharimmune compare to Aura Biosciences?Aura Biosciences (NASDAQ:AURA) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Is AURA or THAR more profitable? Aura Biosciences' return on equity of -78.12% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -78.12% -64.08% Tharimmune N/A -588.45%-264.41% Which has more risk and volatility, AURA or THAR? Aura Biosciences has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Which has preferable earnings and valuation, AURA or THAR? Aura Biosciences is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$106.19M-$1.74N/ATharimmuneN/AN/A-$12.20M-$3.99N/A Do insiders and institutionals hold more shares of AURA or THAR? 96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer AURA or THAR? Aura Biosciences currently has a consensus price target of $20.50, suggesting a potential upside of 169.74%. Given Aura Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Aura Biosciences is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media refer more to AURA or THAR? In the previous week, Aura Biosciences had 3 more articles in the media than Tharimmune. MarketBeat recorded 4 mentions for Aura Biosciences and 1 mentions for Tharimmune. Aura Biosciences' average media sentiment score of 0.14 beat Tharimmune's score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAura Biosciences beats Tharimmune on 9 of the 13 factors compared between the two stocks.How does Tharimmune compare to Avalo Therapeutics?Avalo Therapeutics (NASDAQ:AVTX) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations. Which has more volatility and risk, AVTX or THAR? Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Which has stronger valuation and earnings, AVTX or THAR? Tharimmune has lower revenue, but higher earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$60K14,325.33-$78.26M-$5.46N/ATharimmuneN/AN/A-$12.20M-$3.99N/A Is AVTX or THAR more profitable? Avalo Therapeutics' return on equity of -97.54% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -97.54% -72.42% Tharimmune N/A -588.45%-264.41% Do analysts prefer AVTX or THAR? Avalo Therapeutics presently has a consensus target price of $48.13, suggesting a potential upside of 194.34%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.83Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media prefer AVTX or THAR? In the previous week, Avalo Therapeutics had 12 more articles in the media than Tharimmune. MarketBeat recorded 13 mentions for Avalo Therapeutics and 1 mentions for Tharimmune. Avalo Therapeutics' average media sentiment score of 1.06 beat Tharimmune's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of AVTX or THAR? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAvalo Therapeutics beats Tharimmune on 9 of the 14 factors compared between the two stocks.How does Tharimmune compare to Prothena?Prothena (NASDAQ:PRTA) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Is PRTA or THAR more profitable? Tharimmune has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Prothena-260.92% -43.44% -36.87% Tharimmune N/A -588.45%-264.41% Which has stronger earnings & valuation, PRTA or THAR? Tharimmune has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProthena$9.68M53.16-$244.09M-$2.82N/ATharimmuneN/AN/A-$12.20M-$3.99N/A Which has more volatility & risk, PRTA or THAR? Prothena has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Do analysts prefer PRTA or THAR? Prothena presently has a consensus price target of $21.78, suggesting a potential upside of 121.54%. Given Prothena's stronger consensus rating and higher possible upside, equities analysts clearly believe Prothena is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.36Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor PRTA or THAR? In the previous week, Prothena and Prothena both had 1 articles in the media. Prothena's average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in PRTA or THAR? 97.1% of Prothena shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryProthena beats Tharimmune on 10 of the 14 factors compared between the two stocks.How does Tharimmune compare to Allogene Therapeutics?Allogene Therapeutics (NASDAQ:ALLO) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Which has better earnings & valuation, ALLO or THAR? Tharimmune has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$20K34,515.00-$190.89M-$0.77N/ATharimmuneN/AN/A-$12.20M-$3.99N/A Is ALLO or THAR more profitable? Allogene Therapeutics' return on equity of -56.45% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -56.45% -40.36% Tharimmune N/A -588.45%-264.41% Which has more volatility & risk, ALLO or THAR? Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Do analysts prefer ALLO or THAR? Allogene Therapeutics currently has a consensus price target of $8.52, indicating a potential upside of 326.11%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals have more ownership in ALLO or THAR? 83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ALLO or THAR? In the previous week, Tharimmune had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 1 mentions for Tharimmune and 0 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score. Company Overall Sentiment Allogene Therapeutics Neutral Tharimmune Neutral SummaryAllogene Therapeutics beats Tharimmune on 10 of the 14 factors compared between the two stocks.How does Tharimmune compare to Adlai Nortye?Tharimmune (NASDAQ:THAR) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Which has stronger earnings and valuation, THAR or ANL? Tharimmune has higher earnings, but lower revenue than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$12.20M-$3.99N/AAdlai Nortye$5M95.36-$35.53MN/AN/A Do analysts prefer THAR or ANL? Adlai Nortye has a consensus target price of $21.67, suggesting a potential upside of 81.77%. Given Adlai Nortye's stronger consensus rating and higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Adlai Nortye 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer THAR or ANL? In the previous week, Tharimmune and Tharimmune both had 1 articles in the media. Tharimmune's average media sentiment score of 0.00 equaled Adlai Nortye'saverage media sentiment score. Company Overall Sentiment Tharimmune Neutral Adlai Nortye Neutral Which has more risk and volatility, THAR or ANL? Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Do insiders and institutionals hold more shares of THAR or ANL? 1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is THAR or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -588.45% -264.41% Adlai Nortye N/A N/A N/A SummaryAdlai Nortye beats Tharimmune on 7 of the 10 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition ExportMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.81M$3.38B$6.41B$12.31BDividend YieldN/A2.28%2.76%5.31%P/E Ratio-0.8818.9321.0125.66Price / SalesN/A327.88555.7183.69Price / CashN/A131.8944.5756.72Price / Book5.187.1110.377.14Net Income-$12.20M$24.45M$3.56B$335.72M7 Day Performance-2.76%3.32%5.10%3.03%1 Month Performance-0.85%2.13%3.58%2.88%1 Year Performance159.28%63.43%34.18%35.20% Tharimmune Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune0.0082 of 5 stars$3.52+5.1%N/A+144.5%$132.81MN/AN/A2AURAAura Biosciences2.8639 of 5 stars$7.58+1.4%$20.00+164.0%+27.9%$486.25MN/AN/A50Earnings ReportAVTXAvalo Therapeutics3.497 of 5 stars$16.49+1.2%$48.13+191.9%+318.2%$483.71M$60KN/A40Positive NewsAnalyst RevisionPRTAProthena1.6397 of 5 stars$9.18-1.9%$21.78+137.4%+50.1%$480.31M$9.68MN/A130ALLOAllogene Therapeutics2.5146 of 5 stars$1.91+0.3%$8.52+347.4%+83.5%$466.38M$20KN/A310 Related Companies and Tools Related Companies Aura Biosciences Competitors Avalo Therapeutics Competitors Prothena Competitors Allogene Therapeutics Competitors Adlai Nortye Competitors Ocugen Competitors Shattuck Labs Competitors Upstream Bio Competitors 4D Molecular Therapeutics Competitors Kamada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
